首页> 外文期刊>National Journal of Medical Research >A Prospective Study of Estrogen, Progestrone & Her2Neu Receptor in Cases of Breast Cancer in A Tertiary Care Hospital of Bhavnagar, Gujarat, Western India
【24h】

A Prospective Study of Estrogen, Progestrone & Her2Neu Receptor in Cases of Breast Cancer in A Tertiary Care Hospital of Bhavnagar, Gujarat, Western India

机译:印度西部古吉拉特邦巴夫那加尔三级医院的乳腺癌患者中雌激素,孕酮和Her2Neu受体的前瞻性研究

获取原文
       

摘要

Introduction: Hormonal receptors in breast have an implication on the outcomes of breast cancer in women. The objectives of the study were to know the incidence and therapeutic importance of ER/PR & HER2NEU receptor status and it?s relation to recurrence in breast cancer cases. Methodology: A prospective study was conducted over a period of two years from 2012-2013 on 30 newly diagnosed cases of breast cancer admitted at a tertiary care centre in Bhavnagar. Patientswere clinically staged and either posted for surgery or for neo-adjuvant chemotherapy. In case they were posted for Modified Radical Mastectomy, the specimen of the breast tissue was sent to histo-pathological examination and immuno-histochemistry to determine the ER, PR & HER2NEU receptor status of the breast specimen. On basis of clinical and histo-pathological staging, patient receivedchemotherapy and hormonal therapy. Patients were then monitored for recurrence of breast cancer. Results: The present study found 53.3% breast cancer patients positive for ER, 36.6% patients positive for PR, 53.3% co-positive for ER/PR and 56.6% patients positive for HER2NEU receptor. Breast cancer patients 50 years of age were 25.6 times more likely to test positive for HER2NEU receptors. ER/PR negative patients (who are conventionally not treated with Tamoxifen) were 28.6 times more likely to experience recurrence of breast cancer at six months than EP/PR positive patients who are treated with Tamoxifen. HER2NEU receptor positive patients were 5.2 times more likely to experience recurrence of breast cancer than HER2NEU receptor negative patients. Conclusion: Post-operative recurrence issignificantly less in ER/PR positive breast cancer patients who are treated with Tamoxifen hormonal therapy and is significantly high in HER2NEU receptor positive patients.
机译:简介:乳腺癌中的激素受体对女性乳腺癌的预后有影响。该研究的目的是了解ER / PR和HER2NEU受体状态的发生率和治疗重要性,及其与乳腺癌病例复发的关系。方法:从2012年至2013年,在Bhavnagar一家三级医疗中心对30例新诊断的乳腺癌病例进行了为期两年的前瞻性研究。对患者进行了临床分期,并张贴了手术或新辅助化疗的信息。如果将它们张贴进行改良的根治性乳房切除术,则将乳房组织的标本送去进行组织病理学检查和免疫组织化学以确定乳房标本的ER,PR和HER2NEU受体状态。根据临床和组织病理学分期,对患者进行化学疗法和激素疗法。然后监测患者的乳腺癌复发情况。结果:本研究发现53.3%的乳腺癌患者ER阳性,36.6%的患者PR阳性,53.3%的ER / PR阳性和56.6%的HER2NEU受体阳性。 50岁的乳腺癌患者HER2NEU受体呈阳性反应的可能性高25.6倍。 ER / PR阴性患者(通常不接受他莫昔芬治疗)在六个月内发生乳腺癌复发的可能性比用他莫昔芬治疗的EP / PR阳性患者高28.6倍。 HER2NEU受体阳性患者发生乳腺癌复发的可能性是HER2NEU受体阴性患者的5.2倍。结论:在接受他莫昔芬激素治疗的ER / PR阳性乳腺癌患者中,术后复发显着减少,而在HER2NEU受体阳性患者中则明显较高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号